RxDoctor Payments Data

Peter Torcivia

Psychiatric/Mental Health · San Antonio, TXNPI 1154931723

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.7% of the total across 602 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 17.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,433, 4.1 times the $833 reported in 2021. Among psychiatric/mental health clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$12,781in general payments, 2019–2025

Across 602 payments — averaging $21.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Teva Pharmaceuticals USA, Inc.$2K
  • Alkermes, Inc.$1K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • Axsome Therapeutics, Inc.$1K
  • Otsuka America Pharmaceutical, Inc.$750
  • plus $5K from 29 others

What the payments were for

  • Food & beverage$12,62199%
  • Education$1601%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,781 in reported general payments places this provider in the 95th percentile of 2,724 psychiatric/mental health providers in Texas.

See all psychiatric/mental health providers in Texas

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine11$133,273
BelsomraSuvorexant12$6,214
Aripiprazole35$5,671
Clozapine21$2,979
Lurasidone Hcl24$1,643
Lamotrigine45$733
Olanzapine22$643
Gabapentin27$405
Trazodone Hcl58$392
Quetiapine Fumarate13$352
Bupropion XlBupropion Hcl21$318
Bupropion Hcl SrBupropion Hcl23$266
Duloxetine Hcl11$232
Escitalopram Oxalate16$208
Citalopram HbrCitalopram Hydrobromide17$151

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$1,562$133,27311 claims
MerckBelsomra$16$6,21412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 psychiatric/mental health providers in Texas.

Other psychiatric/mental health in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →